Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03896737
Title Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network

multiple myeloma


Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone


Bortezomib + Dexamethasone + Thalidomide

Daratumumab + Ixazomib

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.